Celgene's apremilast improves DMARD-naïve psoriatic arthritis; reimbursement uncertain
This article was originally published in Scrip
The first detailed results from Celgene's Phase III PALACE 4 clinical trial show that apremilast improves the signs and symptoms of psoriatic arthritis in patients who've never taken disease-modifying anti-rheumatic drugs (DMARDs), but it may be difficult to convince health care payers to reimburse the drug's costs in the absence of treatment with older therapies.
You may also be interested in...
Public Company Edition: Codiak, Kiromic, Aligos and Opthea have fallen below their initial public offering values, while Tarsus and Praxis are trading higher. Also, 5AM, MPM and Cormorant took biotech SPACs public and Evotec led recent non-IPO financings with a €250m private placement.
Private Company Edition: Venture capital invested in pharma and biotech in 2020 totaled $19.5m through Q3, just $400m below the full-year record total of $19.9bn in 2018. Also, Canaan and Catalio reveal new VC funds, while Talaris’s $115m series B leads recent financings.
Biopharma executives discussed their strategies for treating chronic diseases during the Cell and Gene Meeting on the Mesa, including R&D and regulatory considerations.